Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Isoprenaline is a sympathomimetic beta-adrenergic agonist. It increases heart rate, causes peripheral vasodilation and has bronchodilator properties. Indicated in the treatment of bradycardia and heart block, and bronchoconstriction in anesthesia. Intravenous or inhaled administration
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, moderate protein binding) makes transfer to breast milk possible, but its very short half-life (5 minutes) makes it difficult.
Its very low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk, except in the premature and in the immediate neonatal period in which there may be greater intestinal permeability.
Depending on the clinical status of the mother, half an hour (6 T½) after finishing the administration of isoprenaline, she can breastfeed without risk to the infant.